Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC
Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC
Read moreThu, 10th Oct 2019 08:39
Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC
Read moreAffimer Unit Performance Helps Avacta Revenue Beat Market Forecasts
Read more(Sharecast News) - Biotherapeutics development outfit Avacta doubled revenues in the 17-month period ended 31 December 2019 as it was boosted by an initial milestone payment from LG Chem.
Read moreAvacta Group Hires Vectura Group CFO Fry As Non-Executive Director
Read more(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.
Read moreAvacta To Establish Gene Therapy Joint Venture With Daewoong Pharma
Read moreAvacta Expands Contract With LG Chem After First Programme Completes
Read more(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on the 'Affimer' therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas on Wednesday.
Read moreAvacta Non-Executive Sam Williams Steps Down After General Meeting
Read moreAvacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs
Read moreAvacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates
Read more(Sharecast News) - Avacta Group announced on Thursday that it has partnered with life sciences company Selexis to develop the Chinese hamster ovary (CHO) cell line, which will be used to manufacture Avacta's first 'Affimer' clinical candidate for first-time-in-human clinical trials.
Read moreLONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a
Read moreLONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a
Read more